Neuroprotective potential of ferulic acid in the rotenone model of Parkinson’s disease

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 5499-5510

  Ojha, Shreesh ^a   Javed, Hayate ^b   Azimullah, Sheikh ^a   Khair, Salema B Abul ^b   Haque, M Emdadul ^b  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Neurodegeneration; Neuroinflammation; Neurotoxicity; Reactive oxygen species

Indexed keywords

CALCIUM BINDING PROTEIN; CATALASE; CYCLOOXYGENASE 2; FERULIC ACID; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; IONIZED CALCIUM BINDING ADAPTOR MOLECULE 1; MALONALDEHYDE; ROTENONE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; AIF1 PROTEIN, RAT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AUTACOID; BIOLOGICAL MARKER; COUMARIC ACID; CYTOKINE; NEUROPROTECTIVE AGENT; NOS2 PROTEIN, RAT; PTGS2 PROTEIN, RAT; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASTROCYTE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG STRUCTURE; LIPID PEROXIDATION; MALE; MESENCEPHALON; MICROGLIA; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; RAT; RAT MODEL; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL; BRAIN; CELL PROTECTION; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; METABOLISM; NERVE DEGENERATION; PARKINSONIAN DISORDERS; PATHOLOGY; PATHOPHYSIOLOGY; TIME FACTOR; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BIOMARKERS; BRAIN; CALCIUM-BINDING PROTEINS; COUMARIC ACIDS; CYCLOOXYGENASE 2; CYTOKINES; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE; INFLAMMATION MEDIATORS; LIPID PEROXIDATION; MALE; MICROFILAMENT PROTEINS; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; ROTENONE; TIME FACTORS;

EID: 84944089029     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S90616     Document Type: Article

References (40)

1. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157(11):1015–1022.
2. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A. 1998;95(11):6469–6473.
3. Olanow CW, Schapira A, Agid Y. Causes of cell death and prospects for neuroprotection in Parkinson’s disease. Ann Neurol. 2003;53(suppl 3):1–170.
4. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology. 1996;47(6 suppl 3):S161–S170.
5. Schapira AH, Olanow CW, Greenamyre JT, Bezard E. Slowing of neurodegeneration in Parkinson’s disease and Huntington’s disease: future therapeutic perspectives. Lancet. 2014;384(9942):545–555.
6. Al Dakheel A, Kalia LV, Lang AE. Pathogenesis-targeted disease-modifying therapies in Parkinson disease. Neurotherapeutics. 2014;11(1):6–23.
7. Sutachan JJ, Casas Z, Albarracin SL, et al. Cellular and molecular mechanisms of antioxidants in Parkinson’s disease. Nutr Neurosci. 2012;15(3):120–126.
8. Albarracin SL, Stab B, Casas Z, et al. Effects of natural antioxidants in neurodegenerative disease. Nutr Neurosci. 2012;15(1):1–9.
9. Song JX, Sze SC, Ng TB, et al. Anti-parkinsonian drug discovery from herbal medicines: what have we got from neurotoxic models? J Ethnopharmacol. 2012;139(3):698–711.
10. Takeda A, Nyssen OP, Syed A, Jansen E, Bueno-de-Mesquita B, Gallo V. Vitamin A and carotenoids and the risk of Parkinson’s disease: a systematic review and meta-analysis. Neuroepidemiology. 2014;42(1):25–38.
11. Koppula S, Kumar H, More SV, Lim HW, Hong SM, Choi DK. Recent updates in redox regulation and free radical scavenging effects by herbal products in experimental models of Parkinson’s disease. Molecules. 2012;17(10):11391–11420.
12. Picone P, Bondi ML, Montana G, et al. Ferulic acid inhibits oxidative stress and cell death induced by Ab oligomers: improved delivery by solid lipid nanoparticles. Free Radic Res. 2009;43(11):1133–1145.
13. Yabe T, Hirahara H, Harada N, et al. Ferulic acid induces neural progenitor cell proliferation in vitro and in vivo. Neuroscience. 2010;165(2):515–524.
14. Jin Y, Yan EZ, Li XM, et al. Neuroprotective effect of sodium ferulate and signal transduction mechanisms in the aged rat hippocampus. Acta Pharmacol Sin. 2008;29(12):1399–1408.
15. Mori T, Koyama N, Guillot-Sestier MV, Tan J, Town T. Ferulic acid is a nutraceutical β-secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice. PLoS One. 2013;8(2):e55774.
16. Sultana R, Ravagna A, Mohmmad-Abdul H, Calabrese V, Butterfield DA. Ferulic acid ethyl ester protects neurons against amyloid beta-peptide(1-42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J Neurochem. 2005;92(4):749–758.
17. Zhang Z, Wei T, Hou J, Li G, Yu S, Xin W. Iron-induced oxidative damage and apoptosis in cerebellar granule cells: attenuation by tetramethylpyrazine and ferulic acid. Eur J Pharmacol. 2003;467(1–3):41–47.
18. Koh PO. Ferulic acid prevents cerebral ischemic injury-induced reduction of hippocalcin expression. Synapse. 2013;67(7):390–398.
19. Kanski J, Aksenova M, Stoyanova A, Butterfield DA. Ferulic acid antioxidant protection against hydroxyl and peroxyl radical oxidation in synaptosomal and neuronal cell culture systems in vitro: structure-activity studies. J Nutr Biochem. 2002;13(5):273–281.
20. Scapagnini G, Butterfield DA, Colombrita C, Sultana R, Pascale A, Calabrese V. Ethyl ferulate, a lipophilic polyphenol, induces HO-1 and protects rat neurons against oxidative stress. Antioxid Redox Signal. 2004;6(5):811–818.
21. Kim BW, Koppula S, Park SY, et al. Attenuation of neuroinflammatory responses and behavioral deficits by Ligusticum officinale (Makino) Kitag in stimulated microglia and MPTP-induced mouse model of Parkinson’s disease. J Ethnopharmacol. 2015;164:388–397.
22. Nagarajan S, Chellappan DR, Chinnaswamy P, Thulasingam S. Ferulic acid pretreatment mitigates MPTP-induced motor impairment and histopathological alterations in C57BL/6 mice. Pharm Biol. 2015;10:1–11.
23. Przedborski S, Jackson-Lewis V, Naini AB. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem. 2001;76(5):1265–1274.
24. Zhao Q, Cai D, Bai Y. Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson’s disease. Int J Mol Med. 2013;32(4):883–891.
25. Blesa J, Phani S, Jackson-Lewis V, Przedborski S. Classic and new animal models of Parkinson’s disease. J Biomed Biotechnol. 2012;2012:845618.
26. Litteljohn D, Mangano E, Clarke M, Bobyn J, Moloney K, Hayley S. Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson’s disease. Parkinsons Dis. 2011;2011:713517.
27. Johnson ME, Bobrovskaya L. An update on the rotenone models of Parkinson’s disease: their ability to reproduce the features of clinical disease and model gene-environment interactions. Neurotoxicology. 2014;46C:101–116.
28. Cannon JR, Tapias V, Na HM, et al. A highly reproducible rotenone model of Parkinson’s disease. Neurobiol Dis. 2009;34(2):279–290.
29. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci. 2000;3(12):1301–1306.
30. Fujikawa T, Kanada N, Shimada A, et al. Effect of sesamin in Acanthopanax senticosus HARMS on behavioral dysfunction in rotenone-induced parkinsonian rats. Biol Pharm Bull. 2005;28(1):169–172.
31. Sherer TB, Betarbet R, Kim JH, Greenamyre JT. Selective microglial activation in the rat rotenone model of Parkinson’s disease. Neurosci Lett. 2003;341:87–90.
32. Niranjan R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson’s disease: focus on astrocytes. Mol Neurobiol. 2014;49(1):28–38.
33. Anderson G, Maes M. Neurodegeneration in Parkinson’s disease: interactions of oxidative stress, tryptophan catabolites and depression with mitochondria and sirtuins. Mol Neurobiol. 2014;49(2):771–783.
34. Celardo I, Martins LM, FAndhi S. Unravelling mitochondrial pathways to Parkinson’s disease. Br J Pharmacol. 2014;171(8):1943–1957.
35. Pigeolet E, Corbisier P, Houbion A, et al. Glutathione peroxidase, superoxide dismutase, and catalase inactivation by peroxides and oxygen derived free radicals. Mech Ageing Dev. 1990;51(3):283–297.
36. Thakur P, Nehru B. Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson’s disease. Neuroscience. 2013;231:420–431.
37. Hartlage-Rübsamen M, Lemke R, Schliebs R. Interleukin-1β, inducible nitric oxide synthase, and nuclear factor-κB are induced in morphologically distinct microglia after rat hippocampal lipopolysaccharide/interferon-γ injection. J Neurosci Res. 1999;57(3):388–398.
38. Lee JK, Tran T, Tansey M. Neuroinflammation in Parkinson’s disease. J Neuroimmune Pharmacol. 2009;4(4):419–429.
39. Chen X, Tansey MG. The role of neuroinflammation in Parkinson’s disease. In: Minagar A, editor. Neuroinflammation. Vol 18. Oxford: Elsevier; 2011:401–420.
40. Rogers J, Kovelowski CJ. Inflammatory mechanism in Parkinson’s disease. In: Wood PL, editor. Neuroinflammation: Mechanisms and Management. Totowa, NJ: Humana Press; 2003:391–403.